Business Context and Reporting Period
Company: OXIS International, Inc. (Note: Metadata referenced GT Biopharma, but filing content is for OXIS International, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2009
Business Overview: OXIS focuses on the development of nutraceutical and therapeutic products targeting oxidative stress, specifically utilizing patents for Ergothioneine. The company sold its assay business division (BioCheck) in December 2008 and is no longer operating that segment. The company is classified as a "Smaller Reporting Company."
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Total Revenue | $35,000 | $676,000 |
| Gross Profit | $15,000 | $252,000 |
| Net Loss | $(641,000) | $(3,627,000) |
| Cash and Cash Equivalents (End of Period) | $44,000 | $232,000 |
| Net Cash Used in Operating Activities | $(211,000) | $41,000 |
| Total Current Liabilities | $4,963,000 | $4,270,000 |
| Accumulated Deficit | $(75,495,000) | $(74,854,000) |
Debt and Liquidity: The company holds significant debt obligations, including $2,123,000 in convertible debentures and $72,000 in demand notes (net of discount). A derivative liability of $543,000 is recorded on the balance sheet. Cash on hand ($44,000) is insufficient to sustain operations through the remainder of 2009.
Material Changes vs. Prior Period
- Revenue Decline: Product revenues dropped from $676,000 to $35,000 for the six-month period. This decrease is primarily attributable to the sale of the assay kit division in December 2008.
- Net Loss Reduction: While the company remains unprofitable, the net loss decreased significantly from $3.6 million to $641,000. The prior year loss was heavily impacted by a $2.9 million loss on the disposal of discontinued operations and a $396,000 non-cash expense related to warrant liabilities.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased from $737,000 to $370,000, driven by reduced non-cash compensation, overhead, and staff reductions. Research and development expenses were $0 in the current period compared to $56,000 in the prior period.
- Derivative Liabilities: The change in value of warrant and derivative liabilities resulted in a $46,000 expense in the current period, compared to a $396,000 expense in the prior period.
Outlook, Risks, and Contingencies
Going Concern: Management explicitly states that the current rate of cash usage raises "substantial doubt" about the company's ability to continue as a going concern. The company is actively seeking additional equity or debt financing to sustain operations.
Debt Defaults and Foreclosure: The company is in default on its October 2006 convertible debentures, having missed monthly redemption payments since February 2007. In June 2008, a creditor (Bristol Investment Fund, Ltd.) foreclosed on collateral, purchasing the company's majority interest in BioCheck Inc. and OXIS Therapeutics Inc. for a credit bid of $60,000, leaving a deficiency balance of approximately $2.7 million.
Recent Financing (Subsequent Event): On October 1, 2009, the company entered into a financing arrangement for up to $2,000,000 in convertible debentures and warrants. Proceeds are held in escrow pending settlement with existing creditors. This transaction included a Standstill and Forbearance Agreement with Bristol Investment Fund, Ltd., temporarily halting enforcement actions on the defaulted 2006 debentures.
Internal Controls: Management concluded that disclosure controls and procedures were not effective due to material weaknesses. Specifically, all accounting and financial reporting operations are performed by a single individual, resulting in ineffective oversight.
Investor Verification Checklist
- Capital Sufficiency: Verify the status of the October 2009 financing ($2M) and whether funds have been released from escrow to cover operating deficits.
- Debt Settlement: Confirm the terms of the Standstill and Forbearance Agreement with Bristol Investment Fund, Ltd. and the timeline for resolving the $2.7M deficiency from the 2006 debentures.
- Revenue Pipeline: Assess the commercial viability and timeline for the Ergothioneine-based nutraceutical products, as the previous revenue stream (assays) has been sold.
- Dilution Risk: Review the terms of the new convertible debentures and the extensive warrant overhang (over 53 million warrants outstanding) which carry full ratchet anti-dilution provisions.
- Internal Controls: Evaluate the company's plan to remediate the material weakness regarding the single-person accounting function.